Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders
Hepatitis C, Chronic
About this trial
This is an interventional treatment trial for Hepatitis C, Chronic focused on measuring Hepatitis C, Chronic, peginterferon alfa-2b, ribavirin, Amantadine
Eligibility Criteria
Inclusion Criteria: Positive anti-HCV antibody test Patients who did not respond to treatment with standard interferon + ribavirin (HCV RNA+ by PCR in the last month of treatment) Compensated liver disease Neutrophil count over or equal to1000/mm3 Platelet count over or equal to 100 giga/L Haemoglobin over or equal to 10g/dL Patients had to have undergone a post-treatment liver biopsy within a year, showing a METAVIR histological score over or equal to A1F1, without cirrhosis (fibrosis score below F4) ALT over N and HCV RNA+ at screening Exclusion Criteria: Co-infection with hepatitis B or human immunodeficiency virus Any other cause of liver disease Active drug abuse, active alcohol consumption above 40g/day Organ grafts Presence of hepatocellular carcinoma Cardiovascular, metabolic, renal, haematological, neurological or psychiatric disease Patients with previous amantadine use Systemic immunosuppressive or antiviral treatment during the last 24 weeks and those with a history of interferon and/or ribavirin intolerance
Sites / Locations
- Service d'Hépato-Gastroentérologie Hopital Hotel Dieu